Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Pipeline Review, H2 2016 Featuring Nippon Kayaku Co., Ltd. & Shenogen Pharma Group Ltd - Research and Markets

Research and Markets
Posted on: 19 Sep 16

Research and Markets has announced the addition of the "Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Pipeline Review, H2 2016" drug pipelines to their offering.

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) pipeline Target constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by Companies and remaining by the Universities/Institutes.

Aryl Hydrocarbon Receptor - Pipeline Review, H2 2016, outlays comprehensive information on the Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) Aryl hydrocarbon receptor is a protein encoded by the AHR gene. It mediates biochemical and toxic effects of halogenated aromatic hydrocarbons. It involved in cell-cycle regulation. It plays an important role in the development and maturation of many tissues. It regulates the circadian clock by inhibiting the basal and circadian expression of the core circadian component PER1. The molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Furthermore, this report also reviews key players involved in Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

Key Topics Covered:

  1. Introduction
  2. Aryl Hydrocarbon Receptor Overview
  3. Therapeutics Development
  4. Pipeline Products for Aryl Hydrocarbon Receptor - Overview
  5. Pipeline Products for Aryl Hydrocarbon Receptor - Comparative Analysis
  6. Aryl Hydrocarbon Receptor - Therapeutics under Development by Companies
  7. Aryl Hydrocarbon Receptor - Therapeutics under Investigation by Universities/Institutes
  8. Aryl Hydrocarbon Receptor Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Aryl Hydrocarbon Receptor - Products under Development by Companies
  13. Aryl Hydrocarbon Receptor - Products under Investigation by Universities/Institutes
  14. Aryl Hydrocarbon Receptor - Companies Involved in Therapeutics Development
  • Nippon Kayaku Co., Ltd.
  • Shenogen Pharma Group Ltd.

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/jzxf8h/aryl_hydrocarbon

Related Topics: Pharmaceuticals

View source version on businesswire.com: http://www.businesswire.com/news/home/20160919006183/en/

Business Wire
www.businesswire.com

Last updated on: 19/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.